Oculus spins off a new biotech; Adimab expands collaborations with Merck and Lilly;

Conversations on Twitter :

 @FierceBiotech: PATH, Inovio zero in on DNA malaria vaccine. News | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline commits venture $$$ to new $250M biotech startup fund--Sanderling 7, coming 9 years after the last one. Story | Follow @JohnCFierce

> Petaluma, CA-based Oculus Innovative Sciences ($OCLS) is spinning off its novel biotechnology business, Ruthigen. Oculus will retain all Microcyn drug and device indications while Ruthigen will focus on RUT58-60, a drug candidate designed to prevent infection in trauma and surgical procedures. Release

> Adimab has expanded its antibody development deals with Eli Lilly ($LLY) and Merck ($MRK). Story

> Life science exec David A. DeWahl, Jr., has taken the helm at Ischemix, which is developing a new drug designed to open narrowed arteries. Story

Medical Device News

 @FierceMedDev: GI Dynamics, Gore call off legal dogs in patent fight. Story | Follow @FierceMedDev

@MarkHFierce: A "smart socket" to connect to limb stump could lead to better prosthetic fit. U.K. scientists are doing all the work. Item | Follow @MarkHFierce

 @DamianFierce: At yesterday's FierceBiotech JPM13 panel, R&D experts debunked some Big Data myths and looked to a bright future. Editor's Corner | Follow @DamianFierce

> Ex-Orthofix manager gets home confinement in Medicare kickback case. Story

> This time, 'cautious optimism' at the J.P. Morgan Healthcare Conference. Editor's Corner

> Stryker: Hip device recalls could cost up to $390M. More

Pharma News

@FiercePharma: That pregnancy-drug/breast cancer liability suit? All wrapped. $LLY, 4 women reach deal on 2nd day of trial. More | Follow @FiercePharma

 @AlisonBFierce: A fast and early flu season here in the U.S. The CDC's weekly flu map looks grim. More | Follow @AlisonBFierce

> Lilly settles suit linking old miscarriage drug to breast cancer. News

> Eyeing Biogen drug, Teva demands review for new MS meds. Story

> FDA backs tech to throw off painkiller addicts. Article

> Don't expect GSK to spin off ViiV anytime soon, R&D chief says. Report

Vaccines News

> Widespread, early flu season grips United States. Item

> HPV-related cancers up despite vaccines from Merck, GSK. Story

> Altravax pulls in $1.2M from NIH. Article

> Pfizer wins Prevenar 13 expansion in EU. News

> India's vaccine prices soar as private companies gain ground. Story

Pharma Manufacturing News

> Hikma acquisition lands 2 plants in Egypt. Report

> Canada taps Tamiflu stash to help Roche meet demand. Article

> FDA inspectors come down hard on Taiwan plant. News

> More plant closings for Valeant. Story

And Finally… Want to survive your middle age? Investigators say a spouse or permanent companion may be key. Story



Suggested Articles

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.